Previous 10 | Next 10 |
home / stock / rvxcf / rvxcf news
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and intera...
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2022) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF), a world leader in epigenetics, or gene regulation, has begun enrollment and dosing of patients in a Phase 2b clinical trial at a site at the University of Alberta Hospital in Edmo...
On Sat, Dec 18 th at 5pm ET broadcast on FOX Business News – BTV-Business Television visits up-and-coming innovative investment opportunities. Discover Companies to Invest In – Watch their TV feature! Azincourt Energy (OTC...
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2021) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF), a world leader in epigenetics, or gene regulation, is in active discussions with the Kingdom of Morocco's Ministry of Health for possible Phase 2 COVID-19 clinical studies within ...
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2021) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) reported that its Apabetalone drug met its primary endpoint in a pulmonary arterial hypertension or 'PAH' investigator led pilot study. Resverlogix, a world leader in epigenetics,...
Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the "Company") in the principal ...
The following healthcare companies have announced actions related to the COVID-19 outbreak: More news on: Covetrus, Inc., Parallax Health Sciences, Inc., Masimo Corporation, Healthcare stocks news, Stocks on the move, Read more ...
In a recent interview (only visible to PRO+ subscribers ), I was asked about obvious shorts. This inspired me to explore the topic further. My search led me to an obscure pack of stocks, some of which I happened to stumble across before. My first thought about obvious shorts is that they ar...
The FDA has granted Breakthrough Therapy status to Resverlogix's ( OTCPK:RVXCF +14.8% ) apabetalone (RVX-208), combined with standard-of-care treatment, including high-intensity statins, for the secondary prevention of major adverse cardiac events in patients with type 2 diabetes and rec...
Resverlogix is a few days away from releasing topline results from their phase 3 clinical trial, BETonMACE, a trial that aims at showing that Apabetalone (RVX208), a BET bromodomain inhibitor, reduces the risk of heart attacks, stroke and cardiac death in a high-risk population of diabetes pat...
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture (the "Debenture") with Sh...
Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to a...
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of a...